Literature DB >> 2550551

Regulation of lymphocyte tumor necrosis factor receptors by IL-2.

L B Owen-Schaub1, W L Crump, G I Morin, E A Grimm.   

Abstract

Activated lymphocytes are known to express TNF receptors. The precise stimuli involved in induction and regulation of these receptors have not been elucidated. Our findings demonstrate that IL-2, alone and in serum-free conditions, can trigger and regulate TNF receptor expression on normal lymphocytes. Flow cytometric analyses demonstrated that the receptor was rapidly induced on CD4, CD8, and CD16+ cells after IL-2 stimulation. Receptors increased with culture duration, became maximal between days 5 and 9, and were maintained for 18 to 20 days in the presence of IL-2. By using 125I-TNF and FITC-TNF binding, we present evidence that IL-2 concentration determines the magnitude of lymphoid TNF receptor expression--influencing both the percentage of TNF-positive cells within the population and the number of receptors/cell. Collectively, our results are persuasive for consideration of IL-2 as a central mediator in the regulation of lymphocyte TNF receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550551

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Fuzheng Qingjie granules potentiate the anticancer effect of cyclophosphamide by regulating cellular immune function and inducing apoptosis in Hepatoma 22 tumor-bearing mice.

Authors:  Xu-Zheng Chen; Zhi-Yun Cao; You-Quan Zhang; Jin-Nong Li; Lian-Ming Liao; Jian Du
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

2.  Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.

Authors:  T Gatanaga; C D Hwang; W Kohr; F Cappuccini; J A Lucci; E W Jeffes; R Lentz; J Tomich; R S Yamamoto; G A Granger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.

Authors:  P Seckinger; J H Zhang; B Hauptmann; J M Dayer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 4.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

5.  Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.

Authors:  R Landmann; U Keilholz; C Scheibenbogen; M Brockhaus; H Gallati; H Denz; M Bargetzi; C Ludwig
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings.

Authors:  R Karttunen; H M Surcel; G Andersson; H P Ekre; E Herva
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

7.  Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Authors:  K Yoneda; T Osaki; T Yamamoto; E Ueta
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  Tumor necrosis factor alpha binding to bacteria: evidence for a high-affinity receptor and alteration of bacterial virulence properties.

Authors:  G Luo; D W Niesel; R A Shaban; E A Grimm; G R Klimpel
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

9.  Molecular characterization and expression of a granzyme of an ectothermic vertebrate with chymase-like activity expressed in the cytotoxic cells of Nile tilapia (Oreochromis niloticus).

Authors:  Kesavannair Praveen; John H Leary; Donald L Evans; Liliana Jaso-Friedmann
Journal:  Immunogenetics       Date:  2006-02-09       Impact factor: 2.846

10.  Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.

Authors:  J Punnonen; P K Heinonen; T Kuoppala; C T Jansen; R Punnonen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.